Two swine ExPEC phages add to the pipeline for AMR alternatives
Bottom line
Researchers reporting in Veterinary Sciences described two lytic bacteriophages, vB_EcoM_S37 and vB_EcoP_S37A, isolated from swine wastewater that infect swine extraintestinal pathogenic Escherichia coli (ExPEC), a pathogen linked to septicemia, meningitis, and polyserositis in pigs. According to the study abstract, both phages were stable across a broad pH range and moderate heat exposure, and one, vB_EcoM_S37, lysed 27 of 62 tested strains, while vB_EcoP_S37A showed narrower activity. The authors also classified vB_EcoP_S37A as a novel Teseptimavirus species and vB_EcoM_S37 as a Mosigvirus phage, adding new genomic data to the growing pipeline of swine-targeted phage candidates. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, the study adds another early-stage option to the conversation around antimicrobial stewardship in swine medicine. ExPEC remains clinically important in pigs, and interest in phage therapy has grown as antimicrobial resistance complicates treatment decisions. Reviews of phage use in swine and livestock suggest the approach is promising, but they also underscore familiar hurdles: narrow host range, formulation and delivery challenges, phage resistance, and the need for in vivo efficacy and field data before routine use. (pmc.ncbi.nlm.nih.gov)
What to watch: The next step is whether these phages move beyond in vitro characterization into cocktail development, animal studies, and translational work aimed at practical use in swine herds. (frontiersin.org)
Key facts
- Study type
- Isolation and genomic characterization of two lytic bacteriophages
- Phages
- vB_EcoM_S37 and vB_EcoP_S37A
- Target pathogen
- Swine extraintestinal pathogenic Escherichia coli (ExPEC)
- Source
- Swine wastewater
- Host range
- vB_EcoM_S37 lysed 27 of 62 tested strains
- Environmental stability
- Stable at pH 4.0 to 11.0 and 40 to 60 °C
- Taxonomy
- vB_EcoP_S37A was classified as a novel Teseptimavirus species
- Taxonomy
- vB_EcoM_S37 was classified as a Mosigvirus phage
- Clinical relevance
- ExPEC is linked to septicemia, meningitis, and polyserositis in pigs
A new Veterinary Sciences paper reports the isolation and genomic characterization of two lytic bacteriophages, vB_EcoM_S37 and vB_EcoP_S37A, that infect swine extraintestinal pathogenic Escherichia coli (ExPEC), a bacterial group associated with systemic disease in pigs. Based on the study abstract, the phages were recovered from swine wastewater and evaluated for morphology, host range, environmental stability, antibacterial activity, and genome features. The work positions vB_EcoP_S37A as a novel Teseptimavirus species and identifies vB_EcoM_S37 as a Mosigvirus phage. (pmc.ncbi.nlm.nih.gov)
The backdrop is familiar to swine veterinarians: ExPEC is one of several pathogenic E. coli pathotypes affecting pigs, and antimicrobial resistance has intensified interest in alternatives to conventional antibiotics. Prior research has described porcine ExPEC as a cause of septicemia, meningitis, and polyserositis, while recent reviews have framed phage therapy as a potentially useful but still developing tool in food-animal production. That broader literature has emphasized both the appeal of phages, including bacterial specificity, and the practical barriers to deployment at farm scale. (link.springer.com)
From the source abstract, the two phages showed optimal multiplicities of infection of 0.01 for vB_EcoM_S37 and 0.1 for vB_EcoP_S37A. Both remained stable at pH 4.0 to 11.0 and at 40 to 60 °C, characteristics that matter when researchers think about storage, formulation, and possible use in variable production environments. The broader-acting phage, vB_EcoM_S37, lysed 43.55% of tested strains, 27 out of 62, while vB_EcoP_S37A appears to have had a narrower host range. That pattern fits the larger phage literature, where single agents often need to be combined into cocktails to expand coverage and reduce the chance of resistance emerging. (pmc.ncbi.nlm.nih.gov)
The taxonomy piece also matters. Mosigvirus and Teseptimavirus sit within well-studied groups of tailed E. coli phages, and newer genomic work continues to refine how these phages are classified and compared. Related studies in livestock and foodborne E. coli have similarly highlighted the value of whole-genome analysis for screening phages for therapeutic potential and for checking that candidate phages do not carry undesirable virulence or antimicrobial resistance genes. I couldn’t confirm the full paper text directly from the publisher during search because the MDPI page returned an access error in-tool, so the details here rely on the abstract and supporting literature rather than a line-by-line reading of the full article. (mdpi.com)
Industry and expert commentary on this specific paper was limited in open web results, but the broader expert view is fairly consistent. Reviews in swine and livestock medicine describe phage therapy as a credible antimicrobial-sparing strategy, especially against resistant E. coli, while cautioning that performance in vitro does not guarantee on-farm success. Delivery route, persistence in the animal, interaction with the microbiome, regulatory pathways, and the need for strain-matched or multi-phage products remain recurring concerns. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, this study is best read as pipeline news rather than practice-changing evidence. It expands the catalog of characterized phages against swine ExPEC and reinforces that wastewater remains a productive source for candidate biologics. But it also illustrates the central challenge in phage development for herd health: a phage can be genomically interesting and biologically stable, yet still cover only part of the clinical strain diversity veterinarians see in the field. That means the practical future likely lies in phage cocktails, adjunct use with antibiotics, or targeted outbreak applications rather than one-phage-fits-all treatment. (sciencedirect.com)
What to watch: The key next markers will be full-genome safety screening details, testing against larger strain panels, any synergy data with antibiotics, and, most importantly, in vivo swine studies that show whether these candidates can improve outcomes under real production conditions. (link.springer.com)